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 Point-of-care (POC) testing is diagnostic 
testing performed outside of a central 
laboratory at the site of patient care, such 
as a hospital, an emergency room, a phy-
sician ’ s o  ce, or at home.  e primary 
advantage of a POC test is its ability to 
provide rapid test results and, thus, facil-
itate earlier treatment. Other advantages 
include the avoidance of specimen 
processing and smaller volumes of spec-
imen needed for testing. Because of the 
convenience of POC testing, the menu of 
analytes available for testing is increasing 
rapidly, and POC testing is believed to 
represent 25 % of the total expenditures 
of laboratory testing dollars. At present, 
more than 40 laboratory clinical analytes 
are available with the POC testing 
method. 1 Although POC testing is a 
relatively new paradigm in laboratory 
analysis, nephrologists have been famil-
iar with this concept for several decades. 
One of the oldest tests available by POC 
testing is the dipstick for urinalysis, 
which is routinely performed in the o  ce 
setting. In addition, the popularity of the 
home pregnancy test is good evidence 
that POC testing is accepted and favored 
by the public. 
  e ability to receive immediate test 
results is a major reason to convert a test 
to POC testing, and the advantage has 
been well documented for certain condi-
tions. One of the greatest success stories 
of POC testing is glucose self-monitor-
ing.  is application has allowed dia-
betic patients to take charge of their 
disease and has been integral to the 
reduction of morbidity and mortality 
due to diabetes over the past 15 years. 2 
Similarly, anticoagulation is better con-
trolled when home testing of pro-
thrombin time is used to adjust the dose 
of warfarin. 3 However, in certain situa-
tions, such as in1 uenza testing in chil-
dren or the assessment of C-reactive 
protein for initiation of antibiotic use, 
the introduction of POC testing as com-
pared with routine laboratory methods 
did not show any bene3 t in patient- or 
provider-related outcomes. 4,5 
 Vaidya and colleagues 6 (this issue) 
describe a study in which they devel-
oped a rapid and sensitive detection 
system (the RenaStick) for urinary kid-
ney injury  molecule-1 (KIM-1) and 
evaluated this system in animal models 
of acute kidney injury (AKI). 6 The 
results demonstrate the multiple advan-
tages of this technique over currently 
available laboratory methods for detec-
tion of KIM-1 as a biomarker for AKI. 
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 A point-of-care device for 
acute kidney injury:  a fantastic, 
futuristic, or frivolous  ‘ measure ’ ? 
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 This Commentary discusses concepts related to the development of the 
point-of-care (POC) diagnostic system and its advantages and 
disadvantages. Also discussed are the patient, provider, and financial 
outcomes that ought to be evaluated before the POC test becomes 
available for clinical use. 
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 ese include greater ease of use, visual 
readout, high sensitivity, and rapid 
detection.  e authors have validated 
the technique in various rodent models 
of AKI (for example, cadmium toxicity, 
gentamicin toxicity, and ischemia /
 reperfusion). In the preclinical models, 
the results were correlated with renal 
histology, KIM-1 staining, and the 
microbead-based KIM-1 assay. Some 
limitations of RenaStick were addressed, 
such as its inability to measure absolute 
values. RenaStick was also tested in a 
small number of human urine samples 
and appears to work well for extremes of 
KIM-1 values. Further testing and vali-
dation of RenaStick in a large cohort of 
human samples and using Standards for 
Reporting of Diagnostic Accuracy 
(STARD)  criteria will be important for 
demonstrating the utility of RenaStick 
for clinical use. 
 Generally, POC testing for a laboratory 
test is developed several years a? er the 
utility of the diagnostic test has been 
established in a clinical setting. It is clear 
that biomarkers of renal tubular-cell 
injury are needed to supplement serum 
creatinine in the early diagnosis and 
management of clinical AKI. Along the 
lines of this research agenda, several 
biomarkers, such as urine neutrophil 
gelatinase-associated lipocalin (NGAL ), 
urine interleukin-18, (LFABP) liver fatty 
acid binding protein, and urine KIM-1, 
are being studied and are in various 
phases of diagnostic test development. 7 
Thus far, none of the biomarkers has 
demonstrated a clear bene3 t across vari-
ous settings of AKI or received approval 
by the US Food and Drug Administra-
tion for clinical use in AKI.  e published 
clinical studies of urine KIM-1 to date are 
small, and it is unclear whether KIM-1 
will be as eE ective a diagnostic test in 
human AKI as it is in the preclinical set-
ting. 8  erefore, at some level, the devel-
opment of RenaStick for clinical use may 
represent the  ‘ skipping of phases ’ in the 
paradigm of diagnostic test develop-
ment. 9 Nonetheless, RenaStick represents 
an exciting development and potentially 
an important milestone in diagnostic 
testing for AKI. 
see technical notes on page 108
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the patient ’ s detriment, as well as increase 
the overall cost of care. Also, because of 
the kidneys ’ ability to dilute and concen-
trate the urine, levels of biomarkers are 
often altered, and results need to be 
expressed in conjunction with urine cre-
atinine to adjust for urine volume.  is 
would require a urine creatinine dipstick 
to be made available along with some 
type of algorithm modifying results on 
the basis of urine creatinine assessment 
to reduce the number of false-positive 
and false-negative results. Although a 
protein-to-creatinine ratio measured in a 
laboratory in a random urine sample  is a 
powerful mechanism for screening for 
chronic kidney disease, the correspond-
ing Micral urine dipstick for proteinuria, 
without urine creatinine, has not revealed 
itself to be adequately sensitive and spe-
ci3 c for the purposes of screening for 
chronic kidney disease. 11  e false-posi-
tive rate and the false-negative rate of the 
Micral dipstick improved signi3 cantly 
when urine dipsticks were used to correct 
for urine dilution via speci3 c gravity, in 
conjunction with results of urine 
Micral. 11 For most of the novel biomark-
ers of AKI, such as urine KIM-1, if the 
biomarkers are increased before the fall 
in glomerular 3 ltration rate, a correction 
for urine volume may be necessary. On 
the other hand, a? er the fall in glomeru-
lar 3 ltration rate with established AKI, 
the changes in urine creatinine due to 
AKI may make a biomarker level signi3 -
cant and contribute to a false-positive 
reading without any absolute change in 
the biomarker excretion. 
 Can we change AKI outcomes with 
POC testing methods such as RenaStick? 
Medical interventions may directly 
impact patient outcome, but laboratory 
tests generally do not.  e ability to link 
the test result to outcome requires a 
strong link between the result and the 
therapeutic intervention. Currently, 
where no therapeutic interventions exist 
for AKI, the availability of test results a 
few minutes earlier will not change out-
comes. It is conceivable, however, that 
POC testing methods may make the con-
duct of a biomarker-intervention trial 
feasible, especially in a multicenter 
design. Medical outcomes in AKI may be 
di  cult to in1 uence in the short term, 
 Despite the many advantages of POC 
testing as discussed above, the rapid 
increase in POC testing has led to con-
cerns regarding its quality and the asso-
ciated risks. The key problems with 
dipsticks are associated with the trade-
oE  of  convenience at the expense of pre-
cision, analytical  problems, and 
personnel training. There are many 
sources of potential error in POC testing 
due to environmental and operator fac-
tors.  e US Food and Drug Administra-
tion has recorded more than 3200 
complaints involving POC testing 
devices.  is is higher than the number 
of complaints issued for any other medi-
cal device, and includes 16 deaths. 10  is 
has led to an increase in regulatory 
requirements and paperwork for nursing 
staE  in inpatient settings. Unlike tradi-
tional laboratory settings where the bulk 
of testing is performed on a few analyz-
ers by a core group of skilled and trained 
technicians, POC testing is conducted by 
a variety of clinical staff on multiple 
devices in many locations. Most clinical 
staff involved in POC testing are not 
trained in laboratory processes and qual-
ity control procedures. In addition, envi-
ronmental factors may affect POC 
testing. For example, urine dipsticks con-
tain chemicals degraded by light, heat, 
and humidity. For this reason, these tests 
should be stored in  dry cabinets, away 
from sources of moisture, such as sinks 
and patient restrooms, with caps replaced 
and tightly covered a? er use. Fluorescent 
lighting can aE ect color discrimination 
on urine dipsticks, so reading under 
bright incandescent lighting is recom-
mended. 1 Other problems, such as dif-
ficulties in managing documentation 
from multiple sites, operators, and 
devices, have created challenges to the 
widespread adoption of POC testing.  e 
advantages and disadvantages of POC 
testing methods, as they pertain to AKI, 
are discussed in  Figure 1 . 
 POC testing has the potential to pro-
vide a quicker test result, but whether a 
faster result translates into improved 
patient care is debatable. Although some 
POC tests are important for patient care, 
others are sometimes unnecessary and 
duplicate preexisting methods. Is POC 
testing necessary for clinical care in AKI, 
where the turnaround time for electro-
lytes and serum creatinine is fairly quick? 
What, if any, clinical decisions will be 
altered with rapid availability of the 
results? Is there an advantage to making 
a quantitative test such as urine KIM-1 
semiquantitative (yes / no versus absolute 
results)? AKI frequently occurs in criti-
cally ill patients, and any errors with POC 
testing and reporting can prove disas-
trous in this setting. POC testing, without 
quality control, can give false results, to 
Disadvantages
PortablePotential for improved clinical
decision making with faster therapeutic
turnaround time
Small sample volume
Unprocessed
samples
Ease of use
Ability to rule out
injury in preclinical
studies
 
Advantages
Clinically focused
operators
Inappropriate unauthorized
testing and overutilization
(with increased costs)
Regulatory compliance
Semiquantitative results
Problems related to urine volume
Inadequate quality control
and documentation
Poor analytic
performance
 Figure 1  |  Schematic drawing of the RenaStick dipstick showing advantages and 
disadvantages of point-of-care testing in the setting of acute kidney injury. 
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and perhaps satisfaction for either the 
patient or the provider can be improved 
with rapid diagnosis of AKI, which also 
would prove to be helpful. For example, 
should dipsticks be given to patients to 
monitor contrast nephropathy, or to 
monitor analgesic nephropathy from 
nonsteroidal anti-in1 ammatory drugs 
during pain crisis? Financial outcomes 
may be precisely quantified, and cost 
saving may be achieved by early dis-
charge with home monitoring for AKI 
using dipsticks. Patient, provider, and 
3 nancial outcomes need to be studied 
further in the setting of AKI and incor-
porated within the clinical studies of 
newer diagnostic tests. 
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 Regardless of  the underlying etiology, 
chronic kidney disease (CKD) is character-
ized by progressive 3 brosis and sclerosis 
that ultimately aE ect all substructures of the 
kidney. Epidemiologic studies have identi-
3 ed several variables that can predict CKD 
outcomes and may therefore be considered 
risk factors for CKD progression.  ese fac-
tors include African-American race, pro-
teinuria, high blood pressure, high dietary 
protein intake, obesity, anemia, dyslipi-
demia, and smoking. In comparison with 
whites, African Americans and Native 
Americans have 3.6 and 1.8 times higher 
incidences of end-stage renal disease 
(ESRD), respectively. 1 Furthermore, 
 African-American race was independently 
associated with a greater rate of decline in 
glomerular 3 ltration rate in the Modi3 ca-
tion of Diet in Renal Disease Study. 2  e 
incident rate of ESRD in the Hispanic pop-
ulation is 1.5 times greater than that in non-
Hispanics. 1 Although mechanisms 
underlying such racial diE erences remain 
to be elucidated, possible explanations 
include an increased prevalence of diabetes 
mellitus, lower nephron number, increased 
susceptibility to salt-sensitive hypertension, 
yet- undiscovered genetic factors, and dif-
ferences in environment, lifestyle, and 
socioeconomic status. 3 
 Identifying treatable risk factors for CKD 
in African Americans has the potential to 
reduce the excess burden of ESRD in this 
population. Because renal 3 brosis is associ-
ated with CKD progression and transform-
ing growth factor-  1 (TGF-  1) likely 
facilitates this 3 brosis, Suthanthiran and col-
leagues explored the hypothesis that TGF-
  1 overexpression occurs more frequently 
in African Americans with ESRD than in 
whites suE ering from the same disease.  is 
group has previously reported that  African 
Americans with hypertension and ESRD 
exhibit higher circulating levels of TGF-  1 
when compared with whites. 4 – 6 In this issue 
of  Kidney  International , 7 Suthanthiran and 
colleagues dig a little bit deeper, using a 
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 Circulating TGF-  1 as a reliable 
biomarker for chronic kidney 
disease progression in the 
African-American population 
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 Progressive renal  fibrosis is common to all chronic kidney diseases 
(CKD). Suthanthiran and colleagues identified a positive association 
between transforming growth factor-  1 and several risk factors for CKD 
progression in African Americans but not in whites . This study offers a 
possible explanation for the higher prevalence of end-stage renal 
disease in African Americans and highlights the need for a better 
therapeutic strategy for this population. 
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